Neuropathic pain
Pregabalin is indicated for the treatment of peripheral and central neuropathic pain in adults.
Epilepsy
Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary
generalisation.
Generalised anxiety disorder
Pregabalin is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Posology
The dose range is 150 to 600 mg per day given in either two or three divided doses.
Neuropathic pain
Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses.
Based on individual patient response and tolerability, the dose may be increased to 300 mg per day
after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional
7-day interval.
Epilepsy
Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses.
Based on individual patient response and tolerability, the dose may be increased to 300 mg per day
after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.
Generalised anxiety disorder
The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment
should be reassessed regularly.

Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient
response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an
additional week the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day
may be achieved after an additional week.
Discontinuation of pregabalin
In accordance with current clinical practice, if pregabalin has to be discontinued, it is recommended this
should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and
4.8).
Renal impairment
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.
As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction
in patients with compromised renal function must be individualised according to creatinine clearance
(CLcr), as indicated in Table 1 determined using the following formula:

Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients
receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In
addition to the daily dose, a supplementary dose should be given immediately following every 4 hour
haemodialysis treatment (see Table 1).

+ Supplementary dose is a single additional dose
Hepatic impairment
No dose adjustment is required for patients with hepatic impairment (see section 5.2).
Paediatric population
The safety and efficacy of Pregabalin in children below the age of 12 years and in adolescents (12-17
years of age) have not been established. Currently available data are described in sections 4.8, 5.1 and
5.2 but no recommendation on a posology can be made.
Elderly
Elderly patients may require a dose reduction of pregabalin due to a decreased renal function (see
section 5.2).
Method of administration
Pregabalin may be taken with or without food.
Pregabalin is for oral use only.

Diabetic patients
In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin
treatment may need to adjust hypoglycaemic medicinal products.
Hypersensitivity reactions
There have been reports in the postmarketing experience of hypersensitivity reactions, including cases
of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema, such as
facial, perioral, or upper airway swelling occur.
Dizziness, somnolence, loss of consciousness, confusion and mental impairment
Pregabalin treatment has been associated with dizziness and somnolence, which could increase the
occurrence of accidental injury (fall) in the elderly population. There have also been postmarketing
reports of loss of consciousness, confusion and mental impairment. Therefore, patients should be
advised to exercise caution until they are familiar with the potential effects of the medicinal product.
Vision-related effects
In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than
did patients treated with placebo which resolved in a majority of cases with continued dosing. In the
clinical studies where ophthalmologic testing was conducted, the incidence of visual acuity reduction
and visual field changes was greater in pregabalin-treated patients than in placebo-treated patients; the
incidence of fundoscopic changes was greater in placebo-treated patients (see section 5.1). 

In the postmarketing experience, visual adverse reactions have also been reported, including loss of
vision, visual blurring or other changes of visual acuity, many of which were transient. Discontinuation
of pregabalin may result in resolution or improvement of these visual symptoms.
Renal failure
Cases of renal failure have been reported and in some cases discontinuation of pregabalin did show
reversibility of this adverse reaction.
Withdrawal of concomitant anti-epileptic medicinal products
There are insufficient data for the withdrawal of concomitant anti-epileptic medicinal products, once
seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy
on pregabalin.
Withdrawal symptoms
After discontinuation of short-term and long-term treatment with pregabalin, withdrawal symptoms
have been observed in some patients. The following events have been mentioned: insomnia, headache,
nausea, anxiety, diarrhoea, flu syndrome, nervousness, depression, pain, convulsion, hyperhidrosis and
dizziness, suggestive of physical dependence. The patient should be informed about this at the start of
the treatment.
Convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use
or shortly after discontinuing pregabalin.
Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and
severity of withdrawal symptoms may be dose-related.
Congestive heart failure
There have been postmarketing reports of congestive heart failure in some patients receiving
pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during
pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these
patients. Discontinuation of pregabalin may resolve the reaction.
Treatment of central neuropathic pain due to spinal cord injury
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions
in general, central nervous system adverse reactions and especially somnolence was increased. This
may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity
agents) needed for this condition. This should be considered when prescribing pregabalin in this
condition.
Suicidal ideation and behaviour
Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in
several indications. A meta-analysis of randomised placebo controlled studies of anti-epileptic drugs
has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is
not known and the available data do not exclude the possibility of an increased risk for pregabalin. 

Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate
treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical
advice should signs of suicidal ideation or behaviour emerge.
Reduced lower gastrointestinal tract function
There are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g.
intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with
medications that have the potential to produce constipation, such as opioid analgesics. When pregabalin
and opioids will be used in combination, measures to prevent constipation may be considered
(especially in female patients and elderly).
Misuse, abuse potential or dependence
Cases of misuse, abuse and dependence have been reported. Caution should be exercised in patients
with a history of substance abuse and the patient should be monitored for symptoms of pregabalin
misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have
been reported).
Encephalopathy
Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may
precipitate encephalopathy.
Respiratory Depression
Pregabalin has been associated with serious, life-threatening, and fatal respiratory depression. The risk
may be increased with the concomitant use of opioids and other central nervous system (CNS)
depressants, and with conditions such as chronic obstructive pulmonary disease. The elderly are also at
higher risk. Health care providers should start pregabalin at the lowest dose and monitor patients for
symptoms of respiratory depression and sedation when co-prescribing pregabalin with an opioid or
other CNS depressants (eg, benzodiazepines). Patients with underlying respiratory disease and elderly
patients are also at increased risk and should be managed similarly.
 

Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in
humans (< 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro,
and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic
interactions.
In vivo studies and population pharmacokinetic analysis
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed
between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam,
oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics,
insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin
clearance.

Oral contraceptives, norethisterone and/or ethinyl oestradiol
Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol
does not influence the steady-state pharmacokinetics of either substance.
Central nervous system influencing medical products
Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple
oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in
clinically important effects on respiration. In the postmarketing experience, there are reports of
respiratory failure and coma in patients taking pregabalin and other central nervous system (CNS)
depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and
gross motor function caused by oxycodone.
Interactions and the elderly
No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction
studies have only been performed in adults.
Opioids and CNS depressants
Serious respiratory depression may occur with pregabalin when co-administered with opioids and CNS
depressants such as benzodiazepine. Therefore, monitor for symptoms of respiratory depression and
sedation in patients who require concomitant treatment with opioids or CNS depressants.

Women of childbearing potential/Contraception in males and females
As the potential risk for humans is unknown, effective contraception must be used in women of child
bearing potential.
Pregnancy
Pregnancy Category C
There are no adequate data from the use of pregabalin in pregnant women.
Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is
unknown.
Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother
clearly outweighs the potential risk to the foetus).
Breast-feeding
Pregabalin is excreted into human milk (see section 5.2). The effect of pregabalin on newborns/infants
is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue
pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of
therapy for the woman. 

Fertility
There are no clinical data on the effects of pregabalin on female fertility.
In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were
exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on
sperm motility.
A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats
have shown adverse reproductive and developmental effects. The clinical relevance of these findings is
unknown (see section 5.3).

Pregabalin may have minor or moderate influence on the ability to drive and use machines. Pregabalin
may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.
Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous
activities until it is known whether this medicinal product affects their ability to perform these
activities.

The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over
5,600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions
were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all
controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving
pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in
discontinuation from pregabalin treatment groups were dizziness and somnolence.
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more
than one patient, are listed by class and frequency (very common (≥ 1/10); common (≥ 1/100 to <
1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not
known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant
medicinal products.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions
in general, CNS adverse reactions and especially somnolence was increased (see section 4.4).
Additional reactions reported from postmarketing experience are included in italics in the list below.

Table 2. Pregabalin Adverse Drug Reactions

* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).

After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.

Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.

Paediatric population

The pregabalin safety profile observed in four paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n=295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n=175; pharmacokinetic and tolerability study, n=65; and 1 year open label follow on safety study, n=54) was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis. The most common adverse events observed in the 14-day study with pregabalin treatment were somnolence, upper respiratory tract infection, and pyrexia (see sections 4.2, 5.1 and 5.2).

Reporting of suspected adverse reactions

• Saudi Arabia:

The National Pharmacovigilance Centre (NPC):

Fax: +966-11-205-7662

SFDA Call Center: 19999

E-mail: npc.drug@sfda.gov.sa

Website: https://ade.sfda.gov.sa

• Other GCC States:

− Please contact the relevant competent authority.

In the postmarketing experience, the most commonly reported adverse reactions observed when
pregabalin was taken in overdose included somnolence, confusional state, agitation, and restlessness.
Seizures were also reported.
In rare occasions, cases of coma have been reported.
Treatment of pregabalin overdose should include general supportive measures and may include
haemodialysis if necessary (see section 4.2 Table 1).

Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics ATC code: N03AX16
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)-5-
methylhexanoic acid].
Mechanism of action
Pregabalin binds to an auxiliary subunit (α2-δ protein) of voltage-gated calcium channels in the central
nervous system.
Clinical efficacy and safety
Neuropathic pain
Efficacy has been shown in trials in diabetic neuropathy, post herpetic neuralgia and spinal cord injury.
Efficacy has not been studied in other models of neuropathic pain.
Pregabalin has been studied in 10 controlled clinical trials of up to 13 weeks with twice a day dosing
(BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles
for BID and TID dosing regimens were similar.
In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain
was seen by Week 1 and was maintained throughout the treatment period.
In controlled clinical trials in peripheral neuropathic pain 35% of the pregabalin treated patients and
18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing
somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of
patients on placebo. For patients who experienced somnolence the responder rates were 48% on
pregabalin and 16% on placebo.
In the controlled clinical trial in central neuropathic pain 22% of the pregabalin treated patients and 7%
of the patients on placebo had a 50% improvement in pain score.
Epilepsy
Adjunctive Treatment
Pregabalin has been studied in 3 controlled clinical trials of 12 week duration with either BID or TID
dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.

A reduction in seizure frequency was observed by Week 1.
Paediatric population
The efficacy and safety of pregabalin as adjunctive treatment for epilepsy in paediatric patients below
the age of 12 and adolescents has not been established. The adverse events observed in a
pharmacokinetic and tolerability study that enrolled patients from 3 months to 16 years of age (n=65)
with partial onset seizures were similar to those observed in adults. Results of a 12-week placebocontrolled
study of 295 paediatric patients aged 4 to 16 years and a 14 day placebo controlled study of
175 paediatric patients aged 1 month to younger than 4 years of age performed to evaluate the efficacy
and safety of pregabalin as adjunctive therapy for the treatment of partial onset seizures and a 1 year
open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate
that the adverse events of pyrexia and upper respiratory infections were observed more frequently than
in adult studies of patients with epilepsy (see sections 4.2, 4.8 and 5.2).
In the 12-week placebo-controlled study, paediatric patients (4 to 16 years of age) were assigned to
pregabalin 2.5 mg/kg/day (maximum, 150 mg/day), pregabalin 10 mg/kg/day (maximum, 600 mg/day),
or placebo. The percentage of subjects with at least a 50% reduction in partial onset seizures as
compared to baseline was 40.6% of subjects treated with pregabalin 10 mg/kg/day (p=0.0068 versus
placebo), 29.1% of subjects treated with pregabalin 2.5 mg/kg/day (p=0.2600 versus placebo) and
22.6% of those receiving placebo.
In the 14-day placebo-controlled study, paediatric patients (1 month to younger than 4 years of age)
were assigned to pregabalin 7 mg/kg/day, pregabalin 14 mg/kg/day, or placebo. Median 24-hour
seizure frequencies at baseline and at the final visit were 4.7 and 3.8 for pregabalin 7 mg/kg/day, 5.4
and 1.4 for pregabalin 14 mg/kg/day, and 2.9 and 2.3 for placebo, respectively. Pregabalin 14
mg/kg/day significantly reduced the log-transformed partial onset seizure frequency versus placebo
(p=0.0223); pregabalin 7 mg/kg/day did not show improvement relative to placebo.
Monotherapy (newly diagnosed patients)
Pregabalin has been studied in 1 controlled clinical trial of 56 week duration with BID dosing.
Pregabalin did not achieve non-inferiority to lamotrigine based on the 6-month seizure freedom
endpoint. Pregabalin and lamotrigine were similarly safe and well tolerated.
Generalised Anxiety Disorder
Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week
duration and a long-term relapse prevention study with a double-blind relapse prevention phase of 6
months duration.
Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was
observed by Week 1.
In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the
patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.
In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than
did patients treated with placebo which resolved in a majority of cases with continued dosing.

Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated
funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. In these
patients, visual acuity was reduced in 6.5% of patients treated with pregabalin, and 4.8% of placebotreated
patients. Visual field changes were detected in 12.4% of pregabalin-treated, and 11.7% of
placebo-treated patients. Funduscopic changes were observed in 1.7% of pregabalin-treated and 2.1%
of placebo-treated patients.

Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy
receiving anti-epileptic drugs and patients with chronic pain.
Absorption
Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations
occurring within 1 hour following both single and multiple dose administration. Pregabalin oral
bioavailability is estimated to be ≥ 90% and is independent of dose. Following repeated administration,
steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption is decreased when
given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to
approximately 2.5 hours. However, administration of pregabalin with food has no clinically significant
effect on the extent of pregabalin absorption.
Distribution
In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and
monkeys. Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating
rats. In humans, the apparent volume of distribution of pregabalin following oral administration is
approximately 0.56 l/kg. Pregabalin is not bound to plasma proteins.
Biotransformation
Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin,
approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The Nmethylated
derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for
0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin Senantiomer
to the R-enantiomer.
Elimination
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.
Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma clearance and renal clearance are
directly proportional to creatinine clearance (see section 5.2 Renal impairment).
Dose adjustment in patients with reduced renal function or undergoing haemodialysis is necessary (see
section 4.2 Table 1).
Linearity/non-linearity
Pregabalin pharmacokinetics are linear over the recommended daily dose range. Inter-subject
pharmacokinetic variability for pregabalin is low (< 20%). Multiple dose pharmacokinetics are predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma
concentrations of pregabalin.
Gender
Clinical trials indicate that gender does not have a clinically significant influence on the plasma
concentrations of pregabalin.
Renal impairment
Pregabalin clearance is directly proportional to creatinine clearance. In addition, pregabalin is
effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma
pregabalin concentrations are reduced by approximately 50%). Because renal elimination is the major
elimination pathway, dose reduction in patients with renal impairment and dose supplementation
following haemodialysis is necessary (see section 4.2 Table 1).
Hepatic impairment
No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since
pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug
in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma
concentrations.
Paediatric population
Pregabalin pharmacokinetics were evaluated in paediatric patients with epilepsy (age groups: 1 to 23
months, 2 to 6 years, 7 to 11 years and 12 to 16 years) at dose levels of 2.5, 5, 10 and 15 mg/kg/day in a
pharmacokinetic and tolerability study.
After oral administration of pregabalin in paediatric patients in the fasted state, in general, time to reach
peak plasma concentration was similar across the entire age group and occurred 0.5 hours to 2 hours
postdose.
Pregabalin Cmax and AUC parameters increased in a linear manner with increasing dose within each age
group. The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased
body weight adjusted clearance of 43% for these patients in comparison to patients weighing ≥30 kg.
Pregabalin terminal half-life averaged about 3 to 4 hours in paediatric patients up to 6 years of age, and
4 to 6 hours in those 7 years of age and older.
Population pharmacokinetic analysis showed that creatinine clearance was a significant covariate of
pregabalin oral clearance, body weight was a significant covariate of pregabalin apparent oral volume
of distribution, and these relationships were similar in paediatric and adult patients.
Pregabalin pharmacokinetics in patients younger than 3 months old have not been studied (see sections
4.2, 4.8 and 5.1).
Elderly
Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is
consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age related compromised renal function (see
section 4.2 Table 1).
Breast-feeding mothers
The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in
10 lactating women who were at least 12 weeks postpartum. Lactation had little to no influence on
pregabalin pharmacokinetics. Pregabalin was excreted into breast milk with average steady-state
concentrations approximately 76% of those in maternal plasma. The estimated infant dose from breast
milk (assuming mean milk consumption of 150 ml/kg/day) of women receiving 300 mg/day or the
maximum dose of 600 mg/day would be 0.31 or 0.62 mg/kg/day, respectively. These estimated doses
are approximately 7% of the total daily maternal dose on a mg/kg basis.

In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically
relevant doses. In repeated dose toxicity studies in rats and monkeys CNS effects were observed,
including hypoactivity, hyperactivity and ataxia. An increased incidence of retinal atrophy commonly
observed in aged albino rats was seen after long-term exposure to pregabalin at exposures ≥ 5 times the
mean human exposure at the maximum recommended clinical dose.
Pregabalin was not teratogenic in mice, rats or rabbits. Foetal toxicity in rats and rabbits occurred only
at exposures sufficiently above human exposure. In prenatal/postnatal toxicity studies, pregabalin
induced offspring developmental toxicity in rats at exposures > 2 times the maximum recommended
human exposure.
Adverse effects on fertility in male and female rats were only observed at exposures sufficiently in
excess of therapeutic exposure. Adverse effects on male reproductive organs and sperm parameters
were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were
associated with spontaneous degenerative processes in male reproductive organs in the rat. Therefore
the effects were considered of little or no clinical relevance.
Pregabalin is not genotoxic based on results of a battery of in vitro and in vivo tests.
Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. No tumours were
observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended
clinical dose of 600 mg/day. In mice, no increased incidence of tumours was found at exposures similar
to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher
exposures. The non-genotoxic mechanism of pregabalin-induced tumour formation in mice involves
platelet changes and associated endothelial cell proliferation. These platelet changes were not present in
rats or in humans based on short-term and limited long-term clinical data. There is no evidence to
suggest an associated risk to humans.
In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats.
However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical
signs of hyperactivity and bruxism and some changes in growth (transient body weight gain
suppression). Effects on the oestrus cycle were observed at 5-fold the human therapeutic exposure.

Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at > 2 times
the human therapeutic exposure. Nine weeks after exposure, this effect was no longer observable.

Pregelatinized starch, Talc, and Gelatin that contains Sodium lauryl sulphate and Titanium dioxide.

Not applicable.

Keep out of the reach and sight of children.
Do not store above 30 °C.
Store in the original package.
Store in dry place.
Do not use this medicine after the expiry date which is stated on the carton.

Pregabalin 150 mg capsules are packed as Aluminium-PVC/PVDC blisters containing 30 (3x10) hard
capsules in outer carton with Patient Information Leaflet.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist
how to dispose of medicines no longer required. These measures will help to protect the environment.